European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population

Figures

• 

  FIGURE 1. A depiction of the atrial fibrillation prevalence distribution found by each study published to date. 151 This depiction uses the sex‐specific average rates of AF prevalence, grouped by age. The thick line represents average AF prevalence rates by age group, as derived from a pooled analysis of the individual studies weighted by sample size. (Adapted from Andrade et al. Circ Res 2014.) AF, atrial fibrillation.

• 

  FIGURE 2. Sex differences in symptoms related to atrial fibrillationy 144 (Adapted from fig. 2 in Andrade et al. Can J Cardiol 2018).

• 

  FIGURE 3. Investigations and associated risk factors useful to predict the development and progression of AF in HF patients. AF, atrial fibrillation; BNP, B‐type natriuretic peptide; CRP, C‐reactive protein; ECG, electrocardiogram; HF, heart failure; LA, left atrium; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy; MRI, magnetic resonance imaging.

• 

  FIGURE 4. Proceeding of evaluation for cryptogenic stroke. AF, atrial fibrillation; CT, computed tomography; ECG, electrocardiogram; ILR, implantable loop recorder; MRI, magnetic resonance imaging; TOE, transoesophageal echocardiography.

• 

  FIGURE 5. Mortality risk in patients with atrial fibrillation.